Table 3 Cox regression analysis of transplant outcomes using variables derived from the outcome of univariate analysis or established risk factors.

	Relapse			NRM			LFS
	HR	CI	p	HR	CI	p	HR	CI	p
MRD negative at transplant	0.57	0.44–0.73	1e−05	1.31	0.91–0.90	0.15	0.76	0.62–0.94	0.01
Age (per 10 years)	0.96	0.86–1.07	0.42	1.33	1.15–1.53	0.00	1.09	0.99–1.19	0.07
RIC vs. MAC	1.03	0.79–1.37	0.82	0.82	0.58–1.17	0.29	0.93	0.75–1.16	0.53
Good risk cytogenetics vs. all others	0.62	0.46–0.83	0.00	1.19	0.83–1.70	0.36	0.79	0.62–0.99	0.04
Time from diagnosis to transplant	0.98	0.97–0.99	<10⁻⁵	1.00	0.99–1.00	0.34	0.99	0.98–0.99	2e−05
VUD vs. MSD	0.79	0.60–1.04	0.10	1.11	0.77–1.60	0.58	0.90	0.72–1.13	0.39
Female donor to male	0.75	0.52–1.07	0.11	1.30	0.88–1.89	0.20	0.94	0.72–1.22	0.63
In vivo TCD	1.35	1.02–1.79	0.03	0.89	0.62–1.27	0.51	1.13	0.91–1.41	0.27
Patient CMV positive	1.03	0.78–1.36	0.82	1.00	0.71–1.43	0.98	1.01	0.81–1.26	0.9175
Donor CMV positive	0.87	0.66–1.15	0.32	1.39	0.98–1.97	0.06	1.06	0.85–1.31	0.61
Transplant center			0.29			0.16			0.21

	OS			GRFS			AGVHD II–IV
	HR	CI	p	HR	CI	p	HR	CI	p
MRD negative at transplant	1.00	0.77–1.20	0.70	0.69	0.57–0.83	6e−05	0.91	0.69–1.22	0.52
Age (per 10 years)	1.10	1.00–1.20	0.058	1.05	0.97–1.13	0.25	0.94	0.84–1.06	0.29
RIC vs. MAC	1.00	0.78–1.22	0.83	0.98	0.81–1.18	0.80	0.84	0.62–1.14	0.26
Good risk cytogenetics vs. all others	0.72	0.56–0.92	0.01	0.87	0.71–1.06	0.16	1.04	0.76–1.42	0.80
Time from diagnosis to transplant	0.99	0.980–0.99	0.0	1.00	0.99–1.00	0.26	1.00	1.00–1.01	0.16
VUD vs. MSD	0.95	0.75–1.20	0.66	1.14	0.93–1.40	0.20	2.03	1.46–2.81	2e−05
Female donor to male	1.06	0.76–1.32	0.98	1.08	0.86–1.34	0.55	1.48	1.06–2.07	0.02
In vivo TCD	1.10	0.88–1.38	0.40	0.61	0.51–0.74	<10⁻⁵	0.62	0.45–0.84	0.00
Patient CMV positive	0.95	0.76–1.20	0.68	1.17	0.97–1.42	0.11	0.99	0.73–1.33	0.94
Donor CMV positive	1.03	0.82–1.30	0.78	1.60	0.88–1.28	0.56	1.17	0.87–1.56	0.30
Transplant center			0.30			0.34			0.15

	AGVHD III–IV			CGVHD			EXT CGVHD
	HR	CI	p	HR	CI	p	HR	CI	p
MRD negative at transplant	0.65	0.41–1.03	0.06	0.87	0.67–1.12	0.26	0.57	0.40–0.81	0.00
Age (per 10 years)	1.00	0.83–1.21	0.99	1.02	0.92–1.14	0.64	1.00	0.87–1.16	0.99
RIC vs. MAC	1.22	0.74–2.01	0.44	1.04	0.79–1.35	0.80	0.94	0.65–1.37	0.76
Good risk cytogenetics vs. all others	0.96	0.57–1.62	0.89	1.09	0.77–1.31	0.95	1.02	0.71–1.47	0.91
Time from diagnosis to transplant	1.00	0.99–1.01	0.51	1.00	0.10–1.09	0.27	1.06	0.10–1.01	0.15
VUD vs. MSD	1.65	0.98–2.77	0.06	1.15	0.88–1.50	0.32	1.71	1.16–2.53	0.01
Female donor to male	1.12	0.63–2.10	0.70	1.25	0.92–1.70	0.16	1.45	0.95–2.22	0.08
In vivo TCD	0.46	0.28–0.77	0.00	0.43	0.33–0.56	<10⁻⁵	0.18	0.12–0.27	<10⁻⁵
Patient CMV positive	1.06	0.630–1.79	0.83	0.96	0.73–1.24	0.72	1.41	0.96–2.09	0.08
Donor CMV positive	1.52	0.92–2.520	0.10	1.27	0.97–1.64	0.08	1.14	0.78–1.67	0.50
Transplant center			0.36			0.10			0.12

cGVHD chronic graft vs. host disease, aGVHD acute graft vs. host disease, CMV cytomegalovirus, GRFS graft vs. host disease and relapse-free survival, GVHD graft vs. host disease, LFS leukemia-free survival, MAC myeloablative conditioning, MRD measurable residual disease, MSD matched sibling donor, NRM non-relapse mortality, OS overall survival, RIC reduced-intensity conditioning, TCD T cell depletion, MUD volunteer unrelated donor.

Search